The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression

In our previous study, we observed that androgen deprivation therapy (ADT) may induce a compensatory increase in MAPK or JNK signaling. Here, we tested the effects of the MEK inhibitors PD0325901 and GSK1120212, ERK1/2 inhibitor GDC-0994, and the JNK inhibitor AS602801 alone and in combination with...

Full description

Bibliographic Details
Main Authors: Zhenghong Li, Carrie Sun, Sijia Tao, Adeboye O. Osunkoya, Rebecca S. Arnold, John A. Petros, Xiongbing Zu, Carlos S. Moreno
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320301157

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320301157

Similar Items